Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021
June 01 2021 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company
dedicated to the development of cellular therapies designed to
reverse disease, today announced its participation in several
industry and investor events:
- NCVH Annual Conference (June 1-4,
2021)Location: The Roosevelt New
OrleansCompany Attendee: Tariq Imam, Executive
Director and Head of Business Development & LicensingThe NCVH
Annual Conference provides education covering all fields of
peripheral interventions including carotid, renal, femoral and
below the knee procedures as well as stent grafting for aortic
dissections, abdominal aortic aneurysms, thoracic aortic aneurysms
and deep venous interventions. For more information on the
conference and how to register, please visit
https://ncvh.org/meeting/ncvh2021/.
- LD Micro Invitational XI (June 8-10,
2021)Location:
VirtualPresentation Date/Time: June 9, 2021 at
10:30 AM EDTPresenter: David J. Mazzo, PhD,
President and CEOThis three-day, virtual investor conference is
expected to feature around 180 companies, presenting for 25 minutes
each, as well as several influential keynotes. The first day of
this conference will also feature an exceptional one-time event:
the LD Micro Hall of Fame. For more information on the conference
and how to register, please visit
https://ldmicrojune2021.mysequire.com/.
- BIO Digital (June 10-11 & 14-18,
2021)Location: VirtualCompany
Attendee: Tariq Imam, Executive Director and Head of
Business Development & LicensingFor 2021, the BIO International
Convention will be held virtually as BIO Digital. This virtual
gathering of the global biotech industry provides access to key
partners via BIO One-on One Partnering™, educational resources to
help drive your business and the insights you need to continue
critical research and development. For more information on the
conference and how to register, please visit
https://www.bio.org/events/bio-digital.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study in the U.S. for the treatment of
coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12),
recipient of orphan designation for Buerger’s Disease in the U.S.
as well as SAKIGAKE designation and eligible for early conditional
approval in Japan for the treatment of critical limb ischemia
(“CLI”) and Buerger’s Disease based on the results of an ongoing
clinical trial; CLBS201, designed to assess the safety and efficacy
of CD34+ cell therapy as a treatment for diabetic kidney disease
(“DKD”); and OLOGO™ (CLBS14), a Regenerative Medicine Advanced
Therapy (“RMAT”) designated therapy for which the Company is in
discussion with the FDA to finalize a Phase 3 protocol of reduced
size and scope for a confirmatory trial in subjects with no-option
refractory disabling angina (“NORDA”). For more information on the
Company, please visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John
MendittoVice President, Investor Relations and Corporate
CommunicationsPhone: +1-908-842-0084Email: jmenditto@caladrius.com
Media: Real ChemistryKelly WakeleePhone:
610.639.2774Email: kwakelee@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024